OTC Nasalcrom market exclusivity "full basis" for decision requested by Bass & Ullman.
This article was originally published in The Tan Sheet
Executive Summary
OTC NASALCROM MARKET EXCLUSIVITY "FULL BASIS" FOR DECISION REQUESTED by the New York City firm Bass & Ullman on behalf on an unnamed client in a Sept. 9 letter to FDA. The agency granted three years of marketing exclusivity to the cromolyn sodium 4% OTC nasal solution product despite the Jan. 14 citizen petition filed by the law firm objecting to such an award. Bass & Ullman is seeking an "immediate ruling" on the petition "so that affected members of the public can be informed of the bases of FDA action, thereby enabling them to take further appropriate action, including judicial review, if that should be deemed necessary."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: